Analysts predict that Eli Lilly and Company (NYSE:LLY) will report earnings of $1.07 per share for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Eli Lilly and’s earnings, with the highest EPS estimate coming in at $1.10 and the lowest estimate coming in at $1.03. Eli Lilly and reported earnings of $0.95 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 12.6%. The firm is expected to announce its next earnings report on Tuesday, January 30th.

According to Zacks, analysts expect that Eli Lilly and will report full-year earnings of $4.20 per share for the current financial year, with EPS estimates ranging from $4.14 to $4.25. For the next financial year, analysts forecast that the company will report earnings of $4.64 per share, with EPS estimates ranging from $4.50 to $4.84. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Eli Lilly and.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same period in the previous year, the company earned $0.88 EPS. The company’s revenue for the quarter was up 9.0% on a year-over-year basis.

LLY has been the subject of a number of research analyst reports. Berenberg Bank reiterated a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a report on Friday, August 4th. Jefferies Group reiterated a “buy” rating and set a $89.00 price target (down from $94.00) on shares of Eli Lilly and in a report on Thursday, August 24th. Piper Jaffray Companies reiterated a “buy” rating and set a $103.00 price target on shares of Eli Lilly and in a report on Thursday, August 31st. Cowen reiterated a “buy” rating and set a $95.00 price target on shares of Eli Lilly and in a report on Wednesday, October 4th. Finally, Goldman Sachs Group reiterated a “buy” rating and set a $95.00 price target (up from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company’s stock. Eli Lilly and presently has an average rating of “Hold” and an average target price of $90.25.

Shares of Eli Lilly and (NYSE LLY) traded up $0.24 during mid-day trading on Tuesday, hitting $85.05. The stock had a trading volume of 2,659,440 shares, compared to its average volume of 3,673,559. Eli Lilly and has a one year low of $65.66 and a one year high of $89.09. The firm has a market capitalization of $92,525.02, a price-to-earnings ratio of 20.55, a PEG ratio of 1.86 and a beta of 0.34. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a dividend yield of 2.45%. The ex-dividend date is Tuesday, November 14th. Eli Lilly and’s payout ratio is presently 98.58%.

In other news, major shareholder Lilly Endowment Inc sold 180,000 shares of the stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $81.06, for a total transaction of $14,590,800.00. Following the sale, the insider now owns 123,865,804 shares in the company, valued at $10,040,562,072.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the sale, the senior vice president now owns 43,580 shares in the company, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold 772,003 shares of company stock worth $64,837,441 in the last 90 days. Company insiders own 0.20% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. IFM Investors Pty Ltd lifted its stake in Eli Lilly and by 0.8% in the first quarter. IFM Investors Pty Ltd now owns 12,722 shares of the company’s stock valued at $1,070,000 after buying an additional 95 shares during the period. Neuberger Berman Group LLC raised its position in shares of Eli Lilly and by 15.2% during the first quarter. Neuberger Berman Group LLC now owns 2,368,858 shares of the company’s stock worth $199,245,000 after purchasing an additional 311,724 shares during the period. Mastrapasqua Asset Management Inc. raised its position in shares of Eli Lilly and by 29.3% during the first quarter. Mastrapasqua Asset Management Inc. now owns 9,210 shares of the company’s stock worth $775,000 after purchasing an additional 2,085 shares during the period. Fort Washington Investment Advisors Inc. OH raised its position in shares of Eli Lilly and by 0.5% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 57,033 shares of the company’s stock worth $4,797,000 after purchasing an additional 300 shares during the period. Finally, AE Wealth Management LLC raised its position in shares of Eli Lilly and by 8.5% during the first quarter. AE Wealth Management LLC now owns 12,651 shares of the company’s stock worth $1,064,000 after purchasing an additional 991 shares during the period. Institutional investors own 76.45% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/28/zacks-brokerages-anticipate-eli-lilly-and-company-lly-to-announce-1-07-eps.html.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.